The Filing Desk

CorVel vs Myriad Genetics

CorVel CRVL · Myriad Genetics MYGN · Health Care Services

CorVel reported revenue of $958 million in fiscal 2026, 1.2 times Myriad Genetics' $824 million in fiscal 2025. CorVel's revenue grew 7.0% in its latest year, and Myriad Genetics' fell 1.6%. Free cash flow was $110 million at CorVel and −$14 million at Myriad Genetics. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.

Side by side

CorVelMyriad Genetics
Latest fiscal yearFY2026, Mar 31, 2026FY2025, Dec 31, 2025
Revenue$958M$824M
Revenue growth7.0%−1.6%
Revenue growth a year, last 5 years11.6%5.2%
Gross margin24.3%69.9%
Operating margin—−47.0%
Net margin11.5%−44.4%
Free cash flow$110M−$14M
Free cash flow margin11.5%−1.7%
Return on capital—−62.6%
Net debt to EBITDA——
Dividends and buybacks$56M$0M
Change in diluted share count−0.7%2.2%
Last close$85.69$5.66
P/E at the last close36.0×—
Insider trades, last 12 monthssold $21.9 million—
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CorVelMyriad Genetics
Operating margin
Percent of revenue
CorVelMyriad Genetics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CorVelMyriad Genetics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CorVel and Myriad Genetics pages.